In last trading session, Novavax, Inc. (NASDAQ:NVAX) saw 6.99 million shares changing hands with its beta currently measuring 1.98. Company’s recent per share price level of $15.40 trading at -$0.99 or -6.04% at ring of the bell on the day assigns it a market valuation of $2.16B. That closing price of NVAX’s stock is at a discount of -54.94% from its 52-week high price of $23.86 and is indicating a premium of 77.08% from its 52-week low price of $3.53. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 8.45 million shares which gives us an average trading volume of 16.85 million if we extend that period to 3-months.

For Novavax, Inc. (NVAX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.00. Splitting up the data highlights that, out of 15 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 6 suggested the stock as a Hold whereas 9 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.

Novavax, Inc. (NASDAQ:NVAX) trade information

Upright in the red during last session for losing -6.04%, in the last five days NVAX remained trading in the red while hitting it’s week-highest on Thursday, 07/18/24 when the stock touched $15.40 price level, adding 8.82% to its value on the day. Novavax, Inc.’s shares saw a change of 220.83% in year-to-date performance and have moved -2.84% in past 5-day. Novavax, Inc. (NASDAQ:NVAX) showed a performance of 9.84% in past 30-days. Number of shares sold short was 29.53 million shares which calculate 1.82 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 31 to the stock, which implies a rise of 50.32% to its current value. Analysts have been projecting 19 as a low price target for the stock while placing it at a high target of 174. It follows that stock’s current price would drop -23.38% in reaching the projected high whereas dropping to the targeted low would mean a loss of -23.38% for stock’s current value.

Novavax, Inc. (NVAX) estimates and forecasts

Statistics highlight that Novavax, Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company added 261.50% of value to its shares in past 6 months, showing an annual growth rate of 109.06% while that of industry is 15.30. Apart from that, the company came raising its revenue forecast for fiscal year 2024.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 11.55% during past 5 years. In 2024, company’s earnings growth rate is likely to be around 107.83% while estimates for its earnings growth in next 5 years are of 37.90%.

NVAX Dividends

Novavax, Inc. is more likely to be releasing its next quarterly report in August and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Novavax, Inc. (NASDAQ:NVAX)’s Major holders

Insiders are in possession of 4.99% of company’s total shares while institution are holding 50.33 percent of that, with stock having share float percentage of 52.98%. Investors also watch the number of corporate investors in a company very closely, which is 50.33% institutions for Novavax, Inc. that are currently holding shares of the company. STATE STREET CORP is the top institutional holder at NVAX for having 16.91 million shares of worth $80.81 million. And as of 2024-03-31, it was holding 16.7777 of the company’s outstanding shares.

The second largest institutional holder is VANGUARD GROUP INC, which was holding about 13.49 million shares on 2024-03-31. The number of shares represents firm’s hold over 13.3904 of outstanding shares, having a total worth of $64.5 million.